Good morning, everyone. Welcome to Munich Re's Q3 Earnings Call. Andrew Buchanan, our CFO, is today's speaker. And as always, he will kick it off with his opening remarks, and then we will go right into Q&A. Andrew, so please go ahead.
Muenchener Rueckversicherungs Gesellschaft in Muenchen AG
F:MUV2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Earnings Call
Q3 2026
Strong nine-month performance puts Munich Re on track to exceed its annual profit target, as management lifts its full-year net-result outlook; the next renewal cycle remains uncertain.
- EPS
- €13.95
- Expected
- €11.23
- Surprise
- +24.2%
- Stock, day of the call
- +2.0%
Announced on the call
- ATBay acquisition update. Munich Re said it intends to close the previously announced ATBay acquisition early next year, hopes for Q1 or possibly early Q1, and believes the necessary regulatory approvals have been obtained or are in process; management said it was quietly confident of completion.
Management Guidance
What management expects for the next quarter
MUV2 guidance for Q4 2026, Oct–Dec 2026
What management expects further ahead
MUV2 full-year and long-term guidance
Since the previous call: 1 raised
Key Topics
What management and analysts discussed
MUV2 Q3 2026 earnings call key topics
A cautious reserve approach
New since Aug 7Releases made during the first three quarters are provisional and will be replaced by the annual bottom-up reserve review. Management says it will act if it identifies vulnerabilities, while describing the current decision to slow releases as precautionary.
Analysts asked
Management said the reserve decision was stand-alone and was not particularly linked to the loss-component reduction; the annual review will provide more clarity.
Capital deployment priorities
New since Aug 7Capital is to support profitable growth and selective M&A, while shareholders should participate in earnings growth through attractive returns.
Renewals remain a negotiation
Renewal discussions are still evolving, with management expecting downward price pressure but stressing that client priorities and the outcomes of negotiations vary. It is not yet prepared to predict a single price or volume change.
Analysts asked
Management expects continued downward price pressure but said negotiations are ongoing and it cannot yet predict a single price or volume change.
Cyber insurance acquisition progresses
The planned combination of cyber insurance with scanning, monitoring and incident-response services is intended to address smaller businesses’ cybersecurity needs. Management remains confident the announced acquisition will complete, subject to the closing process.
Analysts asked
Management said combining cyber insurance with scanning, monitoring and incident response is strategically compelling, particularly for smaller businesses that may lack dedicated cybersecurity resources.
GSI sharpens exposure oversight
More investment in exposure monitoring, geolocation and modeling has helped GSI better understand accumulated exposure across its entities. Management credits these underwriting improvements alongside the inherent element of chance.
Analysts asked
Management credited improved exposure monitoring and management of concentrations, while noting that chance remains part of insurance underwriting.
Other questions
Management attributed the strength mainly to FX, then the large deal coming through sooner, with modest organic growth also contributing.
Management said the accounts should reflect the business’s actual performance, and that a strong year should be visible in the P&L within accounting policies and auditors’ reasonable limits.
Management characterized the earlier contribution as mainly a timing effect, expecting the deal’s combined-ratio impact to reach equilibrium around year-end, but did not say whether its overall volume would be larger.
Not answered: Whether the overall volume of the large transaction will be larger
Management said discounting on newly incurred claims is reflected in the normalized ratio, while the loss-component effect is replaced with zero in its normalization calculation.
Management said it would not treat the Q3 discounting benefit as the new normal, citing the quarter’s outlier-loss mix and the geographic location of a major loss.
Management said profitable new business consumes risk capital and can lower the solvency ratio while adding positively to own funds, and described this as a normal outcome of putting the balance sheet to work.
Transcript
Transcript
Prepared remarks
Thanks very much, Christian, and good morning to all of you from me as well. With a Q3 result of EUR 1.7 billion, I'm pleased to report another particularly strong quarter, continuing the excellent performance of the first 6 months. Munich Re remains resilient and continues to deliver on ambitious financial targets amid geopolitical uncertainty, heightened capital market volatility and more challenging reinsurance markets.
Very strong operational performance across all lines of business, together with a high reinsurance investment result demonstrate the value of our diversified business model in delivering sustainable earnings.
Importantly, our Q3 results stand out not only for their size, but also for their quality. We were able to deliver this strong performance despite further strengthening our balance sheet, a point I will discuss in more detail later. Another point I would like to highlight is that after 9 months, we are making good progress towards our revised revenue guidance, primarily driven by strong new business in life and health reinsurance and inorganic growth at ERGO International. On a currency-adjusted basis, revenue grew by almost 5% year-on-year in the first 9 months.
We continue to navigate the environment from a position of strength and remain well on track to achieve our targets of the Ambition 2030. Against this backdrop, let me turn to the key drivers of our Q3 earnings, starting with the investment result. Global bond yields rose sharply in the third quarter, as you all know, affecting investment results differently across the group.
At ERGO, it led to a decline in the fair value of fixed income investments directly burdening the investment result, which contributed to the return on investment being a relatively low 2.1%. Bear in mind that the P&L impact is, by contrast, rather small due to policyholder participation. Turning to reinsurance. The ROI amounted to an excellent 4.7%, benefiting from derivative instruments positioned to gain from higher interest rates as well as a positive contribution from commodity investments.
The strong investment result for reinsurance contributed directly to the net result with the impact mostly visible in the P&C reinsurance segment. While the group's return on investment of 3.2% in Q3 was a touch lower than expectations, it remains, however, comfortably within our full year guidance for the first 9 months with a return of 3.9%.
At the same time, higher interest rates lifted our reinvestment yield by 40 basis points during the quarter. We took advantage of attractive yields to reposition our fixed income portfolio, deliberately realizing some losses in the reinsurance business field to secure higher future investment income. The running yield remained at the high level of the previous quarter of 4% despite the seasonal boost from dividends that we enjoyed in the prior quarter.
We increasingly will see the benefits of higher yields gradually earning through to our investment income, which gives us tailwind for next year's earnings. Now I turn to the business fields, starting with reinsurance. The Life and Health reinsurance total technical result of EUR 493 million in Q3 came in above the pro rata rate that we need to meet our ambition for the year. This was supported by positive biometric experience, mainly mortality, which was, however, offset by some assumption updates following adverse experience in specific disability portfolios.
The result from insurance-related financial instruments developed very favorably, supported by strong business growth in this year, which was, to some extent, dampened by negative effects from the rising interest rates. The stock of CSM in Life Re increased further, driven by new business growth and the recognition of further large transactions in Q3, providing a strong foundation for sustainably high technical results. Being ahead of the pro rata total technical result guidance of the first 9 months, we are very well on track to achieve our full year guidance of EUR 1.9 billion.
Now in P&C Reinsurance, we posted a pleasing Q3 results with a combined ratio of 80%, which includes major losses somewhat below our expected level. Higher interest rates increased the discounting benefits on newly incurred claims, which went up to 11.5 combined ratio points in Q3, driven by major losses and at the same time, led to a higher release of loss component. These positive effects on the combined ratio were offset partially by a more cautious approach to the balance sheet, where we chose to release only 2% for basic losses from prior years instead of the usual 6%. This leaves us better able to cater for any adverse claims development going forward.
And as usual, we will reassess reserve uncertainties as part of the annual reserve review in the last quarter of this year. While the overall reserve development continues to be favorable, we will address any areas of potential vulnerability where appropriate in order to be well prepared for the future, potentially also at the cost of a higher normalized combined ratio in Q4.
As indicated already, the normalized combined ratio increased slightly further to 82.4% in Q3, reflecting the gradual earn-in of recent renewals and business mix effects. And this upward trend may continue in Q4, not least due to the large structured transaction mentioned in our Q2 earnings call as well as some modest amounts of seasonality. In any case, with a headline actual combined ratio of 72.2% after 9 months, we expect to beat our full year guidance for P&C Reinsurance.
I will conclude the reinsurance part with Global Specialty Insurance, GSI, which delivered a very pleasing result again. The combined ratio of 83.9% was best than expectations, benefiting from benign major losses. Like in P&C Reinsurance, we expect to beat our full year guidance after achieving a combined ratio below 86% for the first 9 months of the year. In the primary insurance business field, ERGO delivered a strong net result of EUR 263 million in the quarter, well above the pro rata guidance. ERGO Germany within that posted a solid segment result of EUR 118 million.
Technical performance in German Life and Health business was pleasing, primarily driven by a high CSM release and a strong PAA business contribution, supported by continued profitable growth. In P&C, we achieved good technical profitability with a combined ratio of 89.8% in the quarter, while claims reserving remains cautious. The Elgo International business reported a very strong net result of EUR 145 million.
Beyond a solid operating performance, it was supported by the first time full consolidation into our accounts of ElGo China Life Insurance, partly offset by smaller negative one-off effects. Technical profitability in the International Life and Health business was strong and significantly exceeded expectations, reflecting a sustained high CSM release, mainly driven by Spain and Belgium Health and a better-than-expected PAA result.
In P&C, in ERGO International, the combined ratio of 89% met full year guidance, supported by good technical performance across most major markets. Finally, a remark on the group's economic solvency position, which remains very strong. The Solvency II ratio decreased to 301% in Q3. This largely reflected higher capital requirements from profitable business growth, particularly in life and health reinsurance, which were only partly offset by our very strong operating performance in the quarter and by the upward impact of interest rates.
In line with Ambition 2030, we aim to deploy capital through profitable business growth and selective M&A, such as the recently announced forthcoming acquisition of ATBay. At the same time, we aim to ensure that shareholders participate in Munich Re's earnings growth through attractive capital returns.
And in that regard, we will provide an update at our next analyst conference in late February once the full year figures are finalized.
This brings me to the outlook for the full year 2026. Overall, with a net result of EUR 5.7 billion after 9 months, we are firmly on track to exceed our annual profit target once again. This would be for the sixth consecutive year.
As mentioned, Munich Re intends to continue strengthening its balance sheet where appropriate in the fourth quarter, which could involve realizing further disposal losses in our fixed income portfolio to reinvest at higher yields. At the same time, as you know, we have raised our full year net result guidance to EUR 6.6 billion with the increase coming from the reinsurance business field. Looking to next year, we will disclose our financial outlook for 2027 on the 10th of December, by which time our planning process will have been completed.
So I would be grateful if you could be patient enough to save your questions about the guidance for year 2027 to the call that we will host at that time.
Ladies and gentlemen, with this, I'm at the end of my opening remarks. I look forward to answering your questions. But first, I hand back to Christian Becker-Hussong.
Thank you very much, Andrew. Just my usual housekeeping. [Operator Instructions]. And we can go ahead, please.
[Operator Instructions]. And the first question comes from Andrew Baker from Goldman Sachs.
Questions and answers
First one, just on the P&C Re insurance revenue. Can you just help me understand what led to the 5% growth in the third quarter stand-alone? Were there any catch-up effects, I don't know, from the life structure transaction you highlighted in 2Q or something else going on here? Any thoughts here would be really appreciated.
And then secondly, on the normalized P&C Re combined ratio, I appreciate it's in line with your prior guidance. I guess the discount benefit was very favorable. When you set the guidance, were you anticipating the higher discounting benefit in 3Q? And is the 11.5% discount benefit in 3Q a good number to think about going forward, just given, obviously, higher rates, but then there's quite a lot going on, on the reserving side as well.
Thanks a lot, Andrew. It's Andrew here, and thank you to all of you actually for joining us today. I know it's a busy day for insurance results. So I appreciate your interest. On the P&C revenue, look, it's obviously a positive thing. I'm pleased that our revenue has turned out to be resilient in this way and that even though the adjustment that we made at the half year downwards of the revenue guidance was absolutely necessary and the right thing to do. I think the revenue is now holding strong and even looks as if it may exceed those levels that we set.
There are certainly a few contributing factors here. I think I must honestly say that FX is part of that. We enjoyed a modest FX tailwind this time around, and it's certainly refreshing that once in a while, it actually goes in our favor. As you know, we suffered quite a lot from the U.S. dollar weakness of Q2 of last year.
The second thing, you mentioned the large deal that we began to discuss with all of you on the Q2 call. And yes, that does continue to earn in. the volumes that we will show in our revenue numbers do have a slight upwards pattern in this financial year. That's correct. I think it would also be fair to say that some of that business came in the door a bit quicker even than we and our clients had anticipated. So there was certainly some benefit from that. But last but not least, I would say there's also an element of genuine organic expansion in there as well, which I would not completely rule out.
So I think even though P&C reinsurance is in a tough and diligent cycle management phase, as we all know perfectly well, there are still opportunities out there. There is still opportunity to expand coverage. And so some of the reductions that we've seen are also offset by natural growth in pockets.
And then, Andrew, your second question was more about the normalized combined ratio. So we did not know earlier in the year that interest rates were going to move up by 70 basis points in Q3. Having said that, I would say to you, the 11.5% discounting benefit that we had in Q3, part of that you would naturally expect when you have more outliers in the P&L because the more outlier losses you have, the more discounting you have to do in absolute terms, the more combined ratio points of discounting that you get. And in Q1 and Q2, our outlier ratio was very low.
So just in terms of absolute magnitude of the discounting, there was less of it around. where I would say to you, no, I wouldn't consider the 11.5% the new normal is also the particular mix of losses that we had in the quarter. So for example, the largest single outlier loss that we had in the quarter was the earthquake in a place, I believe, called El Choco in Colombia, which we said is about 0.3 billion of our outlier losses.
And I learned -- you always learn something new that the Colombian peso yield curve, I think, is sort of up in double digits. So it's the discounting benefit, let's say, will enjoy a temporary artificial boost in this quarter because of the geographical location of the losses.
The next question comes from Shanti Kang from Bank of America.
The first one was just to get your thoughts into 1127, what your base case is. This morning, we heard one of the primary carriers talking a little bit about securing ag covers. So just to get your thoughts on Ts and Cs would be helpful, too.
And then the second one was just on Life & Health. Obviously, there's been impressive growth there and the new business CSM generation is pretty strong. There's been some impact on the solvency side off the back of higher capital requirements. So I was just wondering how we should think about the trade-off between the Life & Health CSM growth and maybe the own funds generation going forward, just to help us model that a bit better.
Great. So quite different questions there, Shanti. Thank you. So you're keeping me nimble. P&C renewals, I'm going to try and be realistic about what I know and what I don't know. So of course, I've been speaking to our colleagues. And honestly, with 7 weeks to go, part of my message to you today has to be that it's too early to call. Renewal negotiations have started. Discussions are happening. I think that some clients will want to get things done before Christmas, but not all. also depends on the geography.
And so I think there's still a certain amount of, let's call it, price discovery and negotiation taking place. I don't think final battle lines, if I can use a military phrase. I don't think final positions have yet solidified.
So I think everything I have to say here is with due caution. I think it's realistic to say that given the strong level of capitalization of both the reinsurance industry and the primary reinsurance industry and given that we appear to have come through basically unscathed from the North Atlantic hurricane season, that there will continue to be downward price pressure. And I certainly would say that brokers and clients directly will be trying to secure further price reductions.
The extent to which that is successful is difficult to say at this stage. certainly depends a little bit on the performance of the business. I think loss-free portfolios probably have a better shot at getting further price reductions than loss affected ones. You broadened the conversation out to terms and conditions.
What I'm hearing from my colleagues is that there is more talk this time than there was a year ago. So I think the conversation has broadened. It's perhaps not only about price the way it was in this year's renewals. try to get a feeling for whether there's one single theme that's predominant in those discussions.
And the answer is not really. It seems like each client has their own priorities or the things that they would be interested in. I mean, ag covers is one. I think that comes up. There is discussions around prepaid reinstatements is another one that comes up. And then there are some clients that would have more of an interest in widening scope definitions.
So basically, the geographical area or the time period over which you can aggregate losses for the purposes of reinsurance. But all of these things should also come at a price. These things aren't free on a technical basis. And so I think this is probably now going to be the tough edge of the negotiations in some places. at this point, I certainly wouldn't be able to commit to any predictions of a single number, be it price change or volume change. So I'm afraid that's probably the best I can do with 7 weeks still to go.
On Life & Health, it's an interesting one because, of course, our balance sheet is exactly there to be put to work to write profitable business. That's what we're always looking to do. And it's the normal state of the world that when you write profitable business, that does transfer risk, it consumes risk capital, and it brings the Solvency II ratio down. And that's certainly what you would always expect from profitable nat cat business or P&C business.
There's just a peculiarity that some of the larger life deals that we've been writing in recent times have had let's call them, future profits discounted over very large time periods that were, let's say, relatively high in comparison to the short-term impact on the risk capital. And so those deals have had the slightly unintuitive impact that they pushed the ratio up.
In Q3, the deals that we booked in Q3, that wasn't the case. It was more a case of normal service being resumed in the sense that you write profitable deals, they're above hurdle. They do actually add positively to the own funds, but they increase the SCR as well and -- and that leads to the ratio drifting down. And if you think of the point that we've reached now mathematically where we're on 30% solvency ratio.
In order to be -- continue pushing that ratio upwards when you write new deals, you really need a high ratio of profit to risk capital on a deal to continue pushing it up even further. So generally, I would say I treat this as a very positive thing. I'm actually delighted that we are putting the balance sheet to work. We haven't had to compromise on our quality in any way. It's profitable business that we've written. And in some regards, as I say, it's normal service resume that you write good business and the ratio comes down.
The next question comes from Kamran Hossain from JPMorgan.
The first question for me is on the increase to guidance. If I just look at the Q3 numbers, clearly, you've tried to hold back some of the profit, the reserving being one of the examples there. What's the rationale behind increasing the guidance? I'm not convinced you get rewarded for increasing the number to EUR 6.6 billion this year. Just interested in kind of what the decision-making was behind that and why you wouldn't maybe try to put a bit more away, realize some more losses, take more reserve kind of conservatism, et cetera?
The second question is on German GAAP. Clearly, the IFRS result is very positive this year. How is the German GAAP progressing this year? And is it better for you on the German GAAP to put conservatism reserves or realized losses on the investments?
So the EUR 6.6 billion, I think it's important spontaneously. I think it's important that the accounts have at least a degree of integrity in the sense that they need to show what's really happening in the business. And so when we have a good quarter and losses come in below expectation, I think it's appropriate and necessary that the results breathe with that. And I think while many of the things that we do are based on assumptions, and you certainly know that we have some room to maneuver in exercising our judgment.
I think at the end of the day, it's important that the results also reflect what we've actually achieved. And for this year, we have had a very good year, which in the aggregate has exceeded our original expectations. And I think that at some point, it's important that some of that is reflected in the P&L. I think perhaps if the underlying assumption is that we are completely free to, let's say, store away all upsides that arise, I think that's not right.
Actually, I think we can't go that far. I think we have to operate within the accounting policies and within what our auditors consider to be reasonable. And so when we have a great year, I think we show that result. And I think that's what we have done. And I think that in a way, that probably links to your second question because I think also by showing a strong result, we do increase the possibility of higher capital returns to our shareholders, which I think is what they would like to see from us when the results are strong.
And so what I can say to you at this stage is that the German GAAP results are proceeding well. I think that they will support our capital return plans in the short to medium term. And I would also say to you, though, as a precautionary statement, the dynamics are very different because those results under German GAAP come partly from dividends from subsidiaries, partly from single company holdings in the P&L. So they are not consolidated in the way that IFRS results are. But directionally, German GAAP is looking strong, and I'm confident that it will support our capital return strategy going forward.
The next question comes from Will Hardcastle from UBS.
Just on the insurance P&C Re revenue, you mentioned there's some genuine organic expansion. Here are we talking about traditional business or structured? And why aren't we seeing this come through in the GWP that's not growing as much? And if -- I think you said on that large structured transaction, it's come in a bit earlier. I guess, do you expect the overall quantum of the transaction to be bigger now? Or is it just a timing aspect? And how does that interact with the combined ratio impact that's there?
And then just looking at the P&C Re regular income yield, -- it does look elevated now for the past couple of quarters. I accept yields have moved a long way. I'm wondering if there is something that's just boosted that a little bit further this quarter. So you wouldn't want us to take that as the regular income run rate? Or is that -- that's actually the starting point we should think about the higher reinvestment yields from?
Okay. Thanks, Will. So on the revenue question about P&C reinsurance and in particular, the large deal, yes, I did mention that the volume of business came in a bit quicker than we had anticipated. I would consider that largely a timing effect in the sense that the impact that, that deal has on our combined ratio will stabilize a little bit sooner than it would otherwise have stabilized.
So I think it will probably reach a kind of equilibrium level around about the end of this year. So probably when we get to Q4, the normalized combined ratio that we present then, whatever piece of that is attributable to the large deal, that's probably -- that's then, let's say, the sustainable level, which we might then carry through into next year, probably for a large part of next year. And that deal, I think, will start trailing off in terms of earnings towards the end of next year. So that's the dynamics.
I would say that, let's say, that plateau, that equilibrium point, whatever you want to call it, we're probably going to get there a bit faster than we anticipated.
On the income yield for P&C reinsurance, so there were -- I'm afraid I'm prepared to comment a bit more easily just on the overall running yield on the investment portfolio, which I believe was the 4.0%. So it actually came in exactly the same as the Q2 number.
And there were different effects going on. So where we were, let's say, less good than Q2 or where we suffered relative to Q2 is that we didn't have the European equity dividend season, which we had in Q2. We also didn't have the catch-up effect on inflation-linked bonds, which came through in Q2. So those are reasons why you might even have expected a lower running yield. But what helped us then, what basically closed the gap was actually a good quarter for private equity distributions in Q3, which more or less left us back at the same level that we had in Q2. So that was good.
A couple of other remarks. I think in terms of guiding you as to sustainable running yield, I am cautiously optimistic. I really think the increase in the reinvestment yield to 4.7% in Q3 is good news on this front. I would not yet guide you towards 4% as being the permanent level. I think when I was asked this last time or perhaps the time before I was suggesting to you somewhere in the middle between 3.5%, which is our overall target for the return on investment and the 4%. So let's call it something more like 3.7% with maybe potential for some upwards drift.
As I say, I'm cautiously optimistic about that also because the 4.7% reinvestment yield that we achieved in Q3 is a good number. But even there, I think some of the reinvestment that we did was in the earlier part of the quarter in July and August before interest rates had increased as much. So I would treat that as good news. I think where you started your question was specifically on P&C reinsurance. And I would just point out to you, there were some more volatile items that are specifically allocated to P&C reinsurance that led to fair value changes being positive, things like that.
So there, I'm talking about the interest rate derivatives that were positioned for an increase in yields. And we also -- although it's rather modest holdings, I think we also benefited from our exposure to oil, which I think was up 30% in the quarter. And even gold was up 3%. So there were a few, let's call them, more volatile contributors.
The next question comes from Ivan Bokhmat from Barclays.
I've got a couple. The first one, please, on Life & Health. Can you talk a little bit about those onerous contracts and adjustments over Q3? I mean, which regions was that affected by? I understand it's disability. And just as additional clarification, would any of these be related to the transactions that you've been writing over the past couple of years?
And then secondly, just on GSI, I think we've had a much stronger combined ratio clearly in the quarter. Despite the fact that there was quite a lot of severe convective storm activity in the U.S., that GSI was picking up quite a lot in the past. I was just wondering if there was any changes made on the way that exposure was taken, whether you're off risk or there's a new reinsurance in place or it's just pure luck?
And maybe one final really small follow-up. You mentioned the loss component for third quarter in P&C Re was also elevated because of interest rate impact. Should we read it then it would not repeat to the same extent in Q4?
Thanks, Ivan. So on Life & Health Reinsurance, -- perhaps let me answer the second part of your question first because it's a very simple and resounding no. So those onerous contracts, the assumption strengthening that we did had absolutely nothing to do with any of the large deals that we've written recently, I'm happy to say.
In terms of where the adjustments took place, it was in a few specific portfolios or specific contracts in a few different places, a little bit in Canada, a little bit in the U.S. and Germany. Nothing to do with Australia, which has also been the perennial difficult spot when it comes to anything to do with disability. And I also hasten to add nothing systematic here, nothing systemic. So not particularly related to one country or one particular kind of product feature or anything like that.
Then moving on to GSI. Yes, a very pleasing combined ratio. I think the colleagues really have done a good job because you're absolutely right, GSI is exposed more to severe convective storms. Firstly, I can say that the good performance is not really driven by external reinsurance. So recoveries from third-party reinsurers did not really play a role in that. I would say from what I've observed in the last few years, that exposure management and management of concentrations has definitely gone to a different level from what we had in the past.
I think the colleagues have invested more in exposure monitoring. I think you can use a lot of geocoding, geolocation and high-definition modeling these days, which allows you to be more precise. I think the colleagues are doing a better job at understanding the combined footprint of all of the GSI entities together and not just each of them in isolation.
And anecdotally, I was given some presentations on this of the losses that we took at the beginning of last year from the L.A. wildfires. And those were heavy and expensive losses. But what is impressive to see actually is how much higher those losses would have been if they had occurred a few years earlier before we started looking so carefully at exposure accumulations. So I think in insurance underwriting, certainly, there's always an element of chance. But on this one, I would actually also give the colleagues some credit for what I perceive to be some good professional improvements in the underwriting operations.
And then I think, Ivan, you sneaked in a third question for which we may forgive you just this once, which was the loss component. So the loss component reduced by 3.3% as a result of higher discounting from the higher yields. That's clearly a onetime effect that wouldn't usually happen, especially it wouldn't usually happen in Q3. I would -- there is some seasonality in the behavior of the loss component. And I would usually expect some kind of release of the loss component in each of the first 3 quarters.
And then I would expect some kind of seasonal increase in Q4 because we allow for all of the -- the large volume of new business that's going to be bound at 1/1 in the renewals. That would be the usual pattern -- but to have a release of the order of 3.3 combined ratio points in Q3 is not something we would usually expect. I don't think you would get that in a world of stable yield curves.
The next question comes from -- sorry.
Sorry, I was just going to finish maybe just as an afterthought Ivan's point, which is why in a world of stable yield curves, the increases and decreases of the loss components over the year would broadly cancel each other out. And so in our normalization calculations, we usually set that yield loss component piece to 0, as you know.
The next question comes from Chris Hartwell from Autonomous.
Just the first question is, I guess, an extension from what Cam was discussing. Given the -- I mean, I suppose to use the phrase honesty of these results in Q3. I was wondering if you could give a little bit more color in terms of the basis for the change in the release in Q3. Is there -- just if you can give some color on what you've observed and if there are any specific sort of underlying books for either recycling release or where you've chosen just to hold back. So that's the first question.
And secondly, just on M&A. I know I appreciate it's quite small. But I was wondering if you could just give a little bit more color on [ Abay. ] And I guess, in particular, it's the second acquisition you've made where the value really is somewhat distant into the future. So I guess in that regard, if you could also sort of just remind us on what you're trying to achieve from that and the broader sort of context of your M&A ambitions?
Thanks very much, Chris. So on the first question, yes, and going back to the EUR 6.6 billion and Cameron's earlier question about the rationale for that. And indeed, I'm arguing the accounts need to faithfully reflect what is actually happening in the world and the performance of the business and our ability to, let's say, maneuver within a reasonable range of best estimates is -- has its limits. And so I think it's actually healthy for all of our stakeholders that when the performance is very good that you actually see a reaction in the P&L. Now regarding the reserve release, the 2% number,
Firstly, I would describe that as precautionary and preliminary. So just to recap, for those of you that haven't heard this before, the way we do things is that in the first 3 quarters of the year, we do so-called bulk releases, which are really top down at portfolio level, which is why they can end up being such nice round numbers like 6.0% or 2.0% because they are really preliminary. And ultimately, what matters is the annual bottom-up review of the reserves, which is in progress now. I have not seen any results yet, but we'll see the results in Q4.
And then those preliminary releases are essentially replaced by the bottom-up portfolio assessment. And so what we do is we do these provisional releases through the year as an attempt to smooth the release somewhat over the year and to not just have an enormous big bang release all in Q4. So within that context, I would say don't overinterpret the 2%. We've just decided to slow down and be a bit more cautious.
Now I would balance that by saying, based on everything I'm seeing, the reserves overall are running in a very satisfactory way. We continue to be very well reserved. And I certainly have no concerns about any big problems or serious reserve strengthenings that we would need to announce in the near future.
So I would want to dispel any fears that may have been triggered by the 2% number. I think you should rather interpret this as a precautionary measure that we've decided to slow down. Now of course, we will look through the portfolio very carefully. And if we find and when we find areas of potential vulnerability where we would want to have more security for the future, where we would want to bolster our resilience to be able to cope with developments that are less good than we currently expect, we will certainly take action. And we tend to be a bit asymmetric in our behavior.
So at the earliest signs of potentially bad news, we tend to strengthen, and we tend to be rather slow to reflect good news. So we will certainly take a look. We will be prudent, maybe even especially prudent. And anticipating that a little bit, we decided we don't need to wait until Q4. We can probably slow down a little bit already in Q3. So hopefully, that gives you a feeling. Now changing gear, you mentioned M&A. You mentioned [indiscernible], and you're right, it's not particularly large. Maybe before I talk about Adbay, maybe if I can take issue a little bit with the second part of your question because you said it's the second acquisition where we have bought something where the profitability is distant.
And of course, the bigger and already completed acquisition from last year is -- next in California, now branded as ERGONxt. And hopefully, everyone has seen the bright pink training kits of Inter Miami Football Club that says ERGONxt on the front. we are sticking to our commitment that, that business will be breakeven by the end of next year. So I would say to you, that's not too distant. And actually, that business is going pretty well, both in terms of volume growth and technical performance.
But now coming back to Adbay, just a quick update. We've announced the deal. We announced it back in August, as you know. The intention continues to be to close that deal early next year. I certainly would hope for Q1, maybe even early Q1, but let us see. And to the best of my knowledge, the necessary regulatory approvals have been obtained or are in the process of being obtained. I think in particular, I don't think there is any concern about antitrust or anything like that. I think the necessary period for objections to be raised has elapsed. And so I think we're quietly confident that we will complete that acquisition.
And I think the strategic logic of that business of combining just cyber insurance as an insurance product with a broader package of services, so scanning, monitoring and incident reaction, so to mitigate losses when an event happens, really makes a lot of sense, even more so in the new world of frontier large language models that seem able to discover weaknesses at machine speed.
And in particular, the kind of businesses that Adbay serves and will continue to serve in the small and medium space are the ones that may not be able to afford their own big IT departments or their own cybersecurity officer. And so this kind of offering, I think, is exactly the kind of thing that they need. So I think the strategic rationale for that is certainly intact.
The next question comes from Vinit Malhotra from Mediobanca.
So my 2 questions are mainly the follow-up, so apologies for that. But just more clarifying things, please. First one is, again, back to the revenue, P&C revenues. And just trying to understand, when you said that it was the large transaction and the organic opportunities, I'm just trying to square the second bit with the fact that renewals were minus 9% this year and last year, minus 1%. So I'm just trying to understand whether the bulk of this surprise growth was indeed the large transaction? Or was there something else in that organic element you wanted to point out to, please? So that's the first thing.
Second thing is, again, just picking up on the reserve release. I know you've elaborated very well already. I'm just curious that is there -- I mean, should we be thinking that because the loss component went to such a magnitude of 3.3%, it allowed you to think about preponing this reserving action because, I mean, it has never happened in Q3, as you said yourself. So I'm just curious whether there was -- or should we draw any link between these 2 outcomes? And there might not be any, but I just want to clarify.
Thank you for your questions. So on the P&C revenue, you are, of course, absolutely right to point out the negative volume change that we reported in our renewal results. And so if I was giving you a rank order of the explanatory factors that drove the quite good year-on-year revenue number for Q3, I would probably have them something like, number one, the FX improvement that we enjoyed; number two, the large deal. And then probably number three, I would have modest amounts of organic growth. So I would have them in that order.
And I would also point out to you that not all of our business is included in our renewal reporting because renewal reporting relates to treaty reinsurance only. So of course, there is also some facultative and corporate business, which is about underwriting more single large cases, which just happens continuously through the year on a sort of ongoing submission basis. And then secondly, don't forget that when we report those renewal numbers to you, of course, we do our best to give you the best possible estimates of the volume impact.
But as we've discussed once or twice before, especially if you take something like the proportional business, -- we don't know exactly what the volumes will be in the proportional business also because our clients don't know either. And so if underlying business production is a bit stronger than expected, it can also be that more of that flows through to us and that the original estimates that we had in our renewal reporting turn out to be a bit on the low side.
So I can't rule out that, that may also be playing a modest role here. And then your second question, which is the loss component, the reduction of 3.3%, which came from the surge in the interest rates, I wouldn't particularly link the 2 things. So I wouldn't particularly say that was 3.3%. So let's pull some levers somewhere else to balance it out. I think -- the decision to go a bit slower on the reserves is a stand-alone decision. And as I said before, I think we'll also know better at the end of the year once we've completed our reserve review.
The next question comes from Ian Pearce from BNP.
The first one was just on sort of your comments around having to reflect the underlying performance and the market movements in the earnings number. I'm particularly thinking about this in relation to the discounting number. And over recent quarters, there's been a lot more volatility in the discounting and the normalized has been more stable if we sort of account for the structured deal. I mean should we just be thinking that if interest rates move, that will be fully reflected in the discounting and that will be fully reflected in the normalized you report? Or how do you think about managing the sort of discounted versus the undiscounted normalized number?
My second question was just on your comments around the large deal and the fact that you expect that to reach the sort of equilibrium by full year. What impact do you expect from that large deal earning through on the normalized combined ratio in Q4? And if I could just sneak in a third, apologies. The ERGO Germany growth -- organic growth number in Q3 looks to have really accelerated. So I think it was 2% at the half year and it was 11% in Q3. Could you just give us some comments on sort of why that's been so strong in Q3?
Right, Ian. So let me go through those and just tell me at the end if I've all of them. So what I would say on the underlying portfolio -- sorry, the underlying performance, the discounting, what we do, our practice for good or for ill in the normalized combined ratio that we present is that the impact of yield curves on the discounting of the newly incurred claims, you basically see in the normalized combined ratio. So in this quarter, you see the 11.5 points of discounting, and that's on the newly incurred claims in the quarter.
And we could have, I guess, decided to define the normalized combined ratio differently and strip that out. Rightly or wrongly, we would not -- we did not do that. But just to be comprehensive in the answer, there are, of course, some other interest rate effects that do get stripped out and normalize.
And specifically, that's the loss component piece that we have just been talking about quite a lot on today's call. The minus 3.3% does not benefit the normalized combined ratio. We just replaced that with 0, which, as I was saying earlier, is what we would have estimated to be kind of over-the-year aggregate in a world of largely stable interest rates. You could debate and you could define it differently, but I think the most important thing is that we're clear about what's in there and what's not in there.
Now regarding the large deal and the earn-in and the equilibrium point, I'm afraid I can't quantify for you separately the combined ratio impact of that one deal. I think we made a decision as a matter of policy because of the commercial significance and the fact that it is a single deal with a single client that we don't publicly break out the economics of that one deal. I think I would say to you, we've said before that the normalized combined ratio continues to have upward pressure, and I think that upwards pressure will continue in Q4. And that will be a mix of continued earn-in of recent renewal results and continued quicker earn-in of that large deal.
And then in ERGO Germany, I would have to say, I do actually think the organic growth in Elgo Germany is quite impressive. So I think for a large and mature market, I'm actually quite pleased. I think the colleagues really deserve some credit for what they have achieved there. I would say there is probably one effect underlying that, which is an update in the accounting treatment of premium adjustments in the Life and Health business, which may have helped us a bit. But I think most of what you see there is organic. And I think that the revenue levels that we have now achieved at ERGO are sustainable. So I'm not particularly predicting a big drop back or dip again in Q4.
There are no more questions at this time. I would now like to turn the conference back over to Christian Becker Hussong for any closing remarks.
Sorry for the interruption here. I think we may have been cut off. Someone just pointed out to me, and it's probably worth mentioning when wanting to put the 11.5 combined ratio points of discounting into perspective that quite a lot of that discounting benefit actually comes from the new outliers that incurred in the quarter.
So remember, I said the 11.5% relates to the newly incurred claims. So quite some piece of that is the outliers. And so the entire outlier impact, both the nominal value of the new outliers, but also any discounting impact that goes along with that is completely normalized away, and it's just replaced with the 18% that we have as our outlier guidance for this year. It actually hasn't come up in today's call so far, but maybe it's a good opportunity for me to also mention that, of course, in hindsight, as a result of the way the business mix has moved, the 18% is probably higher than it needs to be.
So I think our normalized combined ratio probably understates the underlying profitability of the business as such. But that's obviously something we will try and address for next year. Thank you very much.
There are no more questions at this time. I would now like to turn the conference back over to Christian Beker Hussong for any closing remarks.
Yes. Thank you very much. Nothing to add from my side. If you have further questions, please just give us a call. Otherwise, I hope to see all of you very soon again. Thank you for joining, and have a nice day. Thank you. Bye-bye.